Ethnic variations in response to a statin (Evirest)

Journal of Human Hypertension

Volumn 15, Issue , 2001, Pages S87-S89

  Poulter, N R ^a   Caulfield, M ^b   Feder, G ^b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Atorvastatin; Ethnic variations; Lipid changes

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; STATIN; TRIACYLGLYCEROL;

ARTICLE; ASIAN; CARDIOVASCULAR RISK; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG RESPONSE; DYSLIPIDEMIA; ETHNIC DIFFERENCE; FEMALE; HUMAN; HUMAN GENETICS; LIPID STORAGE; MAJOR CLINICAL STUDY; MALE; NEGRO; PREVENTIVE MEDICINE; RANDOMIZED CONTROLLED TRIAL; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; UNITED KINGDOM;

ANTILIPEMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; HUMANS; HYPERLIPIDEMIAS; RANDOMIZED CONTROLLED TRIALS;

EID: 0034794424     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001213     Document Type: Article

References (9)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
2. Shepherd J et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. NEngl J Med 1995; 333: 1301-1307.
3. Sacks FM et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
4. The Long Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardivascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
5. Downs JR et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 79: 1615-1622.
6. Wood D, Durrington P, Poulter N, McInnes G, Rees A, Wray R for the British Cardiac Society, British Hyperli-pidaemia Association, British Hypertension Society, and British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80: S1-S29.
7. Rubins HB et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-418.
8. Frick MH et al. Helsinki Heart Study: primary-preven-tion trial with gemfibrozil in middle-aged men with dyslipidaemia. N Engl J Med 1987; 317: 1237-1245.
9. McKeigue PM, Shal B, Marmot MG. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. Lancet 1991; 337: 382-386.